Shares of Theravance Biopharma (TBPH 1.28%) were mauled in September, along with most other biotech stocks in general.
Does the big sell-off represent a buying opportunity? Read the presentation below to find out.

Despite releasing some good news, a rough month for biotech stocks in general crushed the company's stock.
Shares of Theravance Biopharma (TBPH 1.28%) were mauled in September, along with most other biotech stocks in general.
Does the big sell-off represent a buying opportunity? Read the presentation below to find out.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.